本文選題：Dyadic + 酶技術(shù)�。� 參考：《印染》2015年24期

【摘要】：正年月號,杜邦生物科技(Biosciences)與Dyadic公司簽署協(xié)議,杜邦以7 500萬美元收購Dyadic的酶技術(shù)及產(chǎn)品。其中包括Dyadic的C1技術(shù)平臺(一項真菌表達酶的技術(shù))及廣泛應(yīng)用的液體和干酶制劑。此舉將進一步擴大杜邦工業(yè)生物技術(shù)在全球的領(lǐng)頭羊地位。"C1平臺將補充杜邦世界級的酶表達系統(tǒng),將為我們強大的創(chuàng)新渠道推向市場提供更多的操作靈活性,"杜邦工業(yè)生物科技總裁William F.Feehery稱。"此外,隨著收購Dyadic的商品酶組合,我們期待服務(wù)新的客戶,并為動物營養(yǎng)、食
[Abstract]:DuPont signed an agreement with Dyadic on the date of the year, DuPont bought Dyadic's enzyme technology and products for $75 million, including the Dyadic C1 technology platform (a fungal expression enzyme technology) and the widely used liquid and dry enzyme preparations. This will further expand DuPont industrial biotechnology in the world's lead. "The C1 platform will complement DuPont's world-class enzyme expression system that will provide more operational flexibility for our powerful innovative channels to market," said DuPont industrial biotechnology President William F.Feehery. "In addition, with the purchase of Dyadic's commercial enzyme combination, we look forward to serving new customers and feeding on animal nutrition.
【分類號】：F416.7
，

本文編號：2089795